Figure 1.
Figure 1. Overall survival (A) and progression-free survival (B) of patients treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.

Overall survival (A) and progression-free survival (B) of patients treated either with HD-RIT using 131I-tositumomab and ASCT or C-HDT and ASCT.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal